Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Venetoclax plus rituximab versus bendamustine plus rituximab in relapsed/refractory chronic lymphocytic leukemia
NL-OMON53139Phase 3Active, not recruiting
- Sponsor
- AbbVie Inc.
- Start
- Dec 2014
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of venetoclax in chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL) (2 arms), sponsored by AbbVie Inc. Primary endpoint: Investigator-assessed progression-free survival. Started Dec 2014; status: active, not recruiting.
02
Drugs
venetoclax
03
Conditions
chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL)
Beyond the preview
Go deeper on NL-OMON53139.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON53139.